Fabry disease in children: Agalsidase-beta enzyme replacement therapy

Clinical Genetics

Volumn 83, Issue 5, 2013, Pages 432-438

  Borgwardt, L ^a   Feldt Rasmussen, U ^b   Rasmussen, A K ^b   Ballegaard, M ^b   Meldgaard Lund, A ^a  

^a Department of Clinical Genetics   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Agalsidase beta; Enzyme replacement therapy; Fabry; Pain

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; CREATININE; FABRYZYME; HIGH MOBILITY GROUP B3 PROTEIN; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANHIDROSIS; ARTICLE; CHILD; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DESCRIPTIVE RESEARCH; DIZZINESS; DRUG SAFETY; ENZYME REPLACEMENT; EXERCISE; FABRY DISEASE; FAMILY HISTORY; FEMALE; FEVER; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; NAUSEA; OBSERVATIONAL STUDY; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCHOOL CHILD; STOMACH PAIN; SWEATING; TACHYPNEA; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; URTICARIA; VOMITING;

ALPHA-GALACTOSIDASE; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; INFANT; ISOENZYMES; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875884077     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01947.x     Document Type: Article

References (24)

1. Schiffmann R. Fabry disease. Pharmacol Ther 2009: 122: 65-77.
2. Illsinger S, Luecke T, Langen H et al. Enzyme replacement therapy in an adolescent with Fabry disease. Eur J Pediatr 2003: 162: 522-523.
3. Mills K, Vellodi A, Morris P et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 2004: 163: 595-603.
4. Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr 2009: 168: 1355-1363.
5. Ramaswami U, Wendt S, Pintos-Morell G et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007: 96: 122-127.
6. Ramaswami U, Parini R, Pintos-Morell G et al. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 2011:81: 485-490.
7. Ries M, Clarke JT, Whybra C et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006: 118: 924-932.
8. Schiffmann R, Martin RA, Reimschisel T et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010: 156: 832-837.
9. Tondel C, Laegreid LM, Hirth A et al. Intravenous enzyme substitution therapy in children with Fabry's disease. Tidsskr Nor Laegeforen 2003: 123: 3388-3390.
10. Wraith JE, Tylki-Szymanska A, Guffon N et al. Safety and efficacy of enzyme replacement therapy with agalsidase-beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008: 152: 563-570.
11. Ramaswami U, Parini R, Kampmann C et al. Safety of agalsidase-alfa in patients with Fabry disease under 7 years. Acta Paediatr 2011: 100: 605-611.
12. Piepsz A, Colarinha P, Gordon I et al. Guidelines for glomerular filtration rate determination in children. Eur J Nucl Med 2001: 28: BP31-BP36.
13. Crutchfield KE, Patronas NJ, Dambrosia JM et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998: 50: 1746-1749.
14. Moore DF, Altarescu G, Barker WC et al. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003: 62: 231-240.
15. Schaefer RM, Tylki-Szymanska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009: 69: 2179-2205.
16. Schiffmann R, Murray GJ, Treco D et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000: 97: 365-370.
17. Torvin MA, Winther BF, Feldt-Rasmussen U et al. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 2009: 145: 237-245.
18. Schiffmann R, Waldek S, Benigni A et al. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 2010: 5: 360-364.
19. Kampmann C, Wiethoff CM, Whybra C et al. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 2008: 97: 463-469.
20. Tondel C, Bostad L, Hirth A et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008: 51: 767-776.
21. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002: 13 (Suppl. 2): S139-S143.
22. van Breemen MJ, Rombach SM, Dekker N et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 2011: 1812: 70-76.
23. Ries M, Gupta S, Moore DF et al. Pediatric Fabry disease. Pediatrics 2005: 115: e344-e355.
24. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54months of agalsidase-beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007: 18: 1547-1557.